ASCVD-话题@MedSci

#ASCVD#

32篇内容 | 3136人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1271121, encodeId=20bb12e1121bf, content=<a href='/topic/show?id=6929284181' target=_blank style='color:#2F92EE;'>#ASCVD#</a>, objectTitle=40岁以后，这5项指标一定要定时筛查丨ASCVD和T2DM新指南, objectType=article, longId=178237, objectId=88031e8237cb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=88031e8237cb, replyNumber=0, likeNumber=108, createdTime=2019-08-29, rootId=0, userName=doctorzheng, userId=9d8a96, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=88031e8237cb, moduleTitle=40岁以后，这5项指标一定要定时筛查丨ASCVD和T2DM新指南, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=88031e8237cb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271120, encodeId=f6e712e112098, content=<a href='/topic/show?id=6929284181' target=_blank style='color:#2F92EE;'>#ASCVD#</a>, objectTitle=2019 TES临床实践指南：存在代谢风险患者ASCVD和T2DM的一级预防, objectType=article, longId=177764, objectId=91bf1e77645d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=91bf1e77645d, replyNumber=0, likeNumber=117, createdTime=2019-08-17, rootId=0, userName=doctorzheng, userId=9d8a96, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=91bf1e77645d, moduleTitle=2019 TES临床实践指南：存在代谢风险患者ASCVD和T2DM的一级预防, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=91bf1e77645d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271119, encodeId=611d12e1119e2, content=<a href='/topic/show?id=6929284181' target=_blank style='color:#2F92EE;'>#ASCVD#</a>, objectTitle=ASCVD低风险患者需要调脂吗？答案是：需要！, objectType=article, longId=168869, objectId=2dd5168869e5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2dd5168869e5, replyNumber=0, likeNumber=96, createdTime=2019-06-22, rootId=0, userName=doctorzheng, userId=9d8a96, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2dd5168869e5, moduleTitle=ASCVD低风险患者需要调脂吗？答案是：需要！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2dd5168869e5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271118, encodeId=67ad12e1118ed, content=<a href='/topic/show?id=6929284181' target=_blank style='color:#2F92EE;'>#ASCVD#</a>, objectTitle=早应用早达标：伴多支病变的ASCVD极高危患者血脂管理的新观点, objectType=article, longId=168095, objectId=44e816809555, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=44e816809555, replyNumber=0, likeNumber=93, createdTime=2019-06-12, rootId=0, userName=doctorzheng, userId=9d8a96, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=44e816809555, moduleTitle=早应用早达标：伴多支病变的ASCVD极高危患者血脂管理的新观点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=44e816809555)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271117, encodeId=c0a412e11173b, content=<a href='/topic/show?id=6929284181' target=_blank style='color:#2F92EE;'>#ASCVD#</a>, objectTitle=atherosclerosis：糖尿病患者的Lp（a）水平升高与ASCVD风险进一步增加有关, objectType=article, longId=159664, objectId=2bef15966418, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2bef15966418, replyNumber=0, likeNumber=85, createdTime=2019-02-10, rootId=0, userName=doctorzheng, userId=9d8a96, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2bef15966418, moduleTitle=atherosclerosis：糖尿病患者的Lp（a）水平升高与ASCVD风险进一步增加有关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2bef15966418)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271116, encodeId=fa0612e1116e2, content=<a href='/topic/show?id=6929284181' target=_blank style='color:#2F92EE;'>#ASCVD#</a>, objectTitle=J Clin Lipidol：ASCVD的农村患者对他汀类药物的长期坚持率较高, objectType=article, longId=159660, objectId=d829159660db, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d829159660db, replyNumber=0, likeNumber=85, createdTime=2019-02-10, rootId=0, userName=doctorzheng, userId=9d8a96, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d829159660db, moduleTitle=J Clin Lipidol：ASCVD的农村患者对他汀类药物的长期坚持率较高, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d829159660db)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271115, encodeId=9fd212e1115d9, content=<a href='/topic/show?id=6929284181' target=_blank style='color:#2F92EE;'>#ASCVD#</a>, objectTitle=2018专家共识：合并ASCVD的2型糖尿病患者的药物治疗, objectType=article, longId=155269, objectId=2e5b15526907, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2e5b15526907, replyNumber=0, likeNumber=69, createdTime=2018-12-08, rootId=0, userName=doctorzheng, userId=9d8a96, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2e5b15526907, moduleTitle=2018专家共识：合并ASCVD的2型糖尿病患者的药物治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2e5b15526907)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271114, encodeId=15ff12e111416, content=<a href='/topic/show?id=6929284181' target=_blank style='color:#2F92EE;'>#ASCVD#</a>, objectTitle=2018AHA胆固醇指南更新！如何解读ASCVD二级预防, objectType=article, longId=153426, objectId=466015342693, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=466015342693, replyNumber=0, likeNumber=52, createdTime=2018-11-15, rootId=0, userName=doctorzheng, userId=9d8a96, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=466015342693, moduleTitle=2018AHA胆固醇指南更新！如何解读ASCVD二级预防, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=466015342693)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271113, encodeId=f60912e111363, content=<a href='/topic/show?id=6929284181' target=_blank style='color:#2F92EE;'>#ASCVD#</a>, objectTitle=Ann Intern Med：ASCVD——他汀一级预防指南哪家强？, objectType=article, longId=135768, objectId=0480135e686a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0480135e686a, replyNumber=0, likeNumber=96, createdTime=2018-04-20, rootId=0, userName=doctorzheng, userId=9d8a96, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0480135e686a, moduleTitle=Ann Intern Med：ASCVD——他汀一级预防指南哪家强？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0480135e686a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271112, encodeId=cf6f12e111254, content=<a href='/topic/show?id=6929284181' target=_blank style='color:#2F92EE;'>#ASCVD#</a>, objectTitle=Eur Heart J:：高甘油三酯血症患者他汀预防ASCVD效果如何？, objectType=article, longId=135104, objectId=ead2135104fe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ead2135104fe, replyNumber=0, likeNumber=95, createdTime=2018-04-14, rootId=0, userName=doctorzheng, userId=9d8a96, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ead2135104fe, moduleTitle=Eur Heart J:：高甘油三酯血症患者他汀预防ASCVD效果如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ead2135104fe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271111, encodeId=bbca12e111178, content=<a href='/topic/show?id=6929284181' target=_blank style='color:#2F92EE;'>#ASCVD#</a>, objectTitle=J Am Coll Cardiol.：老年患者他汀一级预防ASCVD 指南建议南辕北辙？, objectType=article, longId=131875, objectId=b76f1318e55e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b76f1318e55e, replyNumber=0, likeNumber=83, createdTime=2018-03-10, rootId=0, userName=doctorzheng, userId=9d8a96, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b76f1318e55e, moduleTitle=J Am Coll Cardiol.：老年患者他汀一级预防ASCVD 指南建议南辕北辙？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b76f1318e55e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271110, encodeId=928412e1110da, content=<a href='/topic/show?id=6929284181' target=_blank style='color:#2F92EE;'>#ASCVD#</a>, objectTitle=2017 ACC关于ASCVD风险管理中降低LDL-C非他汀治疗的专家共识更新要点解读, objectType=article, longId=131009, objectId=4b0e13100995, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4b0e13100995, replyNumber=0, likeNumber=40, createdTime=2018-03-02, rootId=0, userName=doctorzheng, userId=9d8a96, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4b0e13100995, moduleTitle=2017 ACC关于ASCVD风险管理中降低LDL-C非他汀治疗的专家共识更新要点解读, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4b0e13100995)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271109, encodeId=8e9a12e11093a, content=<a href='/topic/show?id=6929284181' target=_blank style='color:#2F92EE;'>#ASCVD#</a>, objectTitle=J Am Heart Assoc：绝经后女性血清FSH水平与10年ASCVD风险负相关, objectType=article, longId=117743, objectId=248711e743ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=248711e743ce, replyNumber=0, likeNumber=109, createdTime=2017-10-28, rootId=0, userName=doctorzheng, userId=9d8a96, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=248711e743ce, moduleTitle=J Am Heart Assoc：绝经后女性血清FSH水平与10年ASCVD风险负相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=248711e743ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271108, encodeId=d6a112e110886, content=<a href='/topic/show?id=6929284181' target=_blank style='color:#2F92EE;'>#ASCVD#</a>, objectTitle=善用他汀，逆转斑块！——如何利用他汀逆转ASCVD患者斑块, objectType=article, longId=107880, objectId=870d10e88072, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=870d10e88072, replyNumber=0, likeNumber=85, createdTime=2017-08-07, rootId=0, userName=doctorzheng, userId=9d8a96, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=870d10e88072, moduleTitle=善用他汀，逆转斑块！——如何利用他汀逆转ASCVD患者斑块, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=870d10e88072)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271107, encodeId=006312e11077f, content=<a href='/topic/show?id=6929284181' target=_blank style='color:#2F92EE;'>#ASCVD#</a>, objectTitle=十年ASCVD发病风险预测模型和风险分层:China-PAR研究, objectType=article, longId=86427, objectId=baf28642e2b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=baf28642e2b, replyNumber=0, likeNumber=59, createdTime=2017-01-04, rootId=0, userName=doctorzheng, userId=9d8a96, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=baf28642e2b, moduleTitle=十年ASCVD发病风险预测模型和风险分层:China-PAR研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=baf28642e2b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271106, encodeId=92ab12e1106c2, content=<a href='/topic/show?id=6929284181' target=_blank style='color:#2F92EE;'>#ASCVD#</a>, objectTitle=JAMA：治疗杂合子FH或ASCVD，PCSK9抑制剂的使用并未达到其成本效益, objectType=article, longId=75393, objectId=b83fe5393ff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b83fe5393ff, replyNumber=0, likeNumber=66, createdTime=2016-08-19, rootId=0, userName=doctorzheng, userId=9d8a96, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b83fe5393ff, moduleTitle=JAMA：治疗杂合子FH或ASCVD，PCSK9抑制剂的使用并未达到其成本效益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b83fe5393ff)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271105, encodeId=dbda12e11057b, content=<a href='/topic/show?id=6929284181' target=_blank style='color:#2F92EE;'>#ASCVD#</a>, objectTitle=JACC：非他汀疗法降低ASCVD风险患者LDL-C专家共识要点, objectType=article, longId=73450, objectId=7c8ee3450d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7c8ee3450d5, replyNumber=0, likeNumber=60, createdTime=2016-07-23, rootId=0, userName=doctorzheng, userId=9d8a96, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7c8ee3450d5, moduleTitle=JACC：非他汀疗法降低ASCVD风险患者LDL-C专家共识要点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7c8ee3450d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271104, encodeId=731b12e1104f2, content=<a href='/topic/show?id=6929284181' target=_blank style='color:#2F92EE;'>#ASCVD#</a>, objectTitle=求同存异，优化治疗 ——以降低ASCVD风险为目标，选择合适强度的他汀治疗, objectType=article, longId=36132, objectId=8d1e3613224, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8d1e3613224, replyNumber=0, likeNumber=82, createdTime=2014-06-08, rootId=0, userName=智慧医人, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8d1e3613224, moduleTitle=求同存异，优化治疗 ——以降低ASCVD风险为目标，选择合适强度的他汀治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8d1e3613224)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1271103, encodeId=074312e11031e, content=<a href='/topic/show?id=6929284181' target=_blank style='color:#2F92EE;'>#ASCVD#</a>, objectTitle=Ann Intern Med：美ASCVD降脂方案比较, objectType=article, longId=30599, objectId=a61930599ac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a61930599ac, replyNumber=0, likeNumber=72, createdTime=2014-02-15, rootId=0, userName=doctorzheng, userId=9d8a96, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a61930599ac, moduleTitle=Ann Intern Med：美ASCVD降脂方案比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a61930599ac)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

ASCVD

2020-05-29

doctorzheng (审核中...)

前往app查看评论内容

#ASCVD#

40岁以后，这5项指标一定要定时筛查丨ASCVD和T2DM新指南

2019-08-29

doctorzheng (审核中...)

前往app查看评论内容

#ASCVD#

2019 TES临床实践指南：存在代谢风险患者ASCVD和T2DM的一级预防

2019-08-17

doctorzheng (审核中...)

前往app查看评论内容

#ASCVD#

ASCVD低风险患者需要调脂吗？答案是：需要！

2019-06-22

doctorzheng (审核中...)

前往app查看评论内容

#ASCVD#

早应用早达标：伴多支病变的ASCVD极高危患者血脂管理的新观点

2019-06-12

doctorzheng (审核中...)

前往app查看评论内容

#ASCVD#

atherosclerosis：糖尿病患者的Lp（a）水平升高与ASCVD风险进一步增加有关

2019-02-10

doctorzheng (审核中...)

前往app查看评论内容

#ASCVD#

J Clin Lipidol：ASCVD的农村患者对他汀类药物的长期坚持率较高

2019-02-10

doctorzheng (审核中...)

前往app查看评论内容

#ASCVD#

2018专家共识：合并ASCVD的2型糖尿病患者的药物治疗

2018-12-08

doctorzheng (审核中...)

前往app查看评论内容

#ASCVD#

2018AHA胆固醇指南更新！如何解读ASCVD二级预防

2018-11-15

doctorzheng (审核中...)

前往app查看评论内容

#ASCVD#

Ann Intern Med：ASCVD——他汀一级预防指南哪家强？

2018-04-20

doctorzheng (审核中...)

前往app查看评论内容

#ASCVD#

Eur Heart J:：高甘油三酯血症患者他汀预防ASCVD效果如何？

2018-04-14

doctorzheng (审核中...)

前往app查看评论内容

#ASCVD#

J Am Coll Cardiol.：老年患者他汀一级预防ASCVD 指南建议南辕北辙？

2018-03-10

doctorzheng (审核中...)

前往app查看评论内容

#ASCVD#

2017 ACC关于ASCVD风险管理中降低LDL-C非他汀治疗的专家共识更新要点解读

2018-03-02

doctorzheng (审核中...)

前往app查看评论内容

#ASCVD#

J Am Heart Assoc：绝经后女性血清FSH水平与10年ASCVD风险负相关

2017-10-28

doctorzheng (审核中...)

前往app查看评论内容

#ASCVD#

善用他汀，逆转斑块！——如何利用他汀逆转ASCVD患者斑块

2017-08-07

doctorzheng (审核中...)

前往app查看评论内容

#ASCVD#

十年ASCVD发病风险预测模型和风险分层:China-PAR研究

2017-01-04

doctorzheng (审核中...)

前往app查看评论内容

#ASCVD#

JAMA：治疗杂合子FH或ASCVD，PCSK9抑制剂的使用并未达到其成本效益

2016-08-19

doctorzheng (审核中...)

前往app查看评论内容

#ASCVD#

JACC：非他汀疗法降低ASCVD风险患者LDL-C专家共识要点

2016-07-23

智慧医人 (审核中...)

前往app查看评论内容

#ASCVD#

求同存异，优化治疗 ——以降低ASCVD风险为目标，选择合适强度的他汀治疗

2014-06-08

doctorzheng (审核中...)

前往app查看评论内容

#ASCVD#

Ann Intern Med：美ASCVD降脂方案比较

2014-02-15

科室
- - 订阅+
  - 更多科室
工具
服务